Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
S. P. Anthony
Research Funding - Plexxikon
I. Puzanov
Consultant or Advisory Role - Plexxikon (U)
P. S. Lin
Employment or Leadership Position - Plexxikon
Stock Ownership - Plexxikon
K. B. Nolop
Employment or Leadership Position - Plexxikon
Stock Ownership - Plexxikon
B. West
Stock Ownership - Plexxikon
D. D. Von Hoff
Research Funding - Plexxikon